• Je něco špatně v tomto záznamu ?

Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study

C. Reijnen, E. Gogou, NCM. Visser, H. Engerud, J. Ramjith, LJM. van der Putten, K. van de Vijver, M. Santacana, P. Bronsert, J. Bulten, M. Hirschfeld, E. Colas, A. Gil-Moreno, A. Reques, G. Mancebo, C. Krakstad, J. Trovik, IS. Haldorsen, J....

. 2020 ; 17 (5) : e1003111. [pub] 20200515

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025008

BACKGROUND: Bayesian networks (BNs) are machine-learning-based computational models that visualize causal relationships and provide insight into the processes underlying disease progression, closely resembling clinical decision-making. Preoperative identification of patients at risk for lymph node metastasis (LNM) is challenging in endometrial cancer, and although several biomarkers are related to LNM, none of them are incorporated in clinical practice. The aim of this study was to develop and externally validate a preoperative BN to predict LNM and outcome in endometrial cancer patients. METHODS AND FINDINGS: Within the European Network for Individualized Treatment of Endometrial Cancer (ENITEC), we performed a retrospective multicenter cohort study including 763 patients, median age 65 years (interquartile range [IQR] 58-71), surgically treated for endometrial cancer between February 1995 and August 2013 at one of the 10 participating European hospitals. A BN was developed using score-based machine learning in addition to expert knowledge. Our main outcome measures were LNM and 5-year disease-specific survival (DSS). Preoperative clinical, histopathological, and molecular biomarkers were included in the network. External validation was performed using 2 prospective study cohorts: the Molecular Markers in Treatment in Endometrial Cancer (MoMaTEC) study cohort, including 446 Norwegian patients, median age 64 years (IQR 59-74), treated between May 2001 and 2010; and the PIpelle Prospective ENDOmetrial carcinoma (PIPENDO) study cohort, including 384 Dutch patients, median age 66 years (IQR 60-73), treated between September 2011 and December 2013. A BN called ENDORISK (preoperative risk stratification in endometrial cancer) was developed including the following predictors: preoperative tumor grade; immunohistochemical expression of estrogen receptor (ER), progesterone receptor (PR), p53, and L1 cell adhesion molecule (L1CAM); cancer antigen 125 serum level; thrombocyte count; imaging results on lymphadenopathy; and cervical cytology. In the MoMaTEC cohort, the area under the curve (AUC) was 0.82 (95% confidence interval [CI] 0.76-0.88) for LNM and 0.82 (95% CI 0.77-0.87) for 5-year DSS. In the PIPENDO cohort, the AUC for 5-year DSS was 0.84 (95% CI 0.78-0.90). The network was well-calibrated. In the MoMaTEC cohort, 249 patients (55.8%) were classified with <5% risk of LNM, with a false-negative rate of 1.6%. A limitation of the study is the use of imputation to correct for missing predictor variables in the development cohort and the retrospective study design. CONCLUSIONS: In this study, we illustrated how BNs can be used for individualizing clinical decision-making in oncology by incorporating easily accessible and multimodal biomarkers. The network shows the complex interactions underlying the carcinogenetic process of endometrial cancer by its graphical representation. A prospective feasibility study will be needed prior to implementation in the clinic.

Biomedical Research Group in Gynecology Vall Hebron Institute of Research Universitat Autònoma de Barcelona CIBERONC Barcelona Spain

Biomedical Research Group in Gynecology Vall Hebron Institute of Research Universitat Autònoma de Barcelona CIBERONC Barcelona Spain Gynecological Department Vall Hebron University Hospital CIBERONC Barcelona Spain

Centre for Cancer Biomarkers Department of Clinical Science University of Bergen Bergen Norway Mohn Medical Imaging and Visualization Centre Department of Radiology Haukeland University Hospital Bergen Norway

Department for Health Evidence Radboud University Medical Center Nijmegen the Netherlands

Department of Computing Sciences Radboud University Nijmegen The Netherlands

Department of Data Science University of Twente Enschede The Netherlands

Department of Gynecology and Obstetrics University Hospital in Brno and Masaryk University Brno Czech Republic

Department of Internal Medicine Hematology and Oncology University Hospital Brno and Masaryk University Brno Czech Republic

Department of Obstetrics and Gynaecology Canisius Wilhelmina Hospital Nijmegen The Netherlands

Department of Obstetrics and Gynaecology Radboud University Medical Center Nijmegen The Netherlands

Department of Obstetrics and Gynaecology Radboud University Medical Center Nijmegen The Netherlands Department of Obstetrics and Gynaecology Canisius Wilhelmina Hospital Nijmegen The Netherlands

Department of Obstetrics and Gynecology Haukeland University Hospital Bergen Norway Centre for Cancer Biomarkers Department of Clinical Science University of Bergen Bergen Norway

Department of Obstetrics and Gynecology Hospital del Mar PSMAR Barcelona Spain

Department of Obstetrics and Gynecology University Medical Center Freiburg Germany Institute of Veterinary Medicine Georg August University Goettingen Germany

Department of Oncology KU Leuven Leuven Belgium Center for Gynecologic Oncology Amsterdam Netherlands Cancer Institute and Amsterdam University Medical Center The Netherlands

Department of Pathology and Molecular Genetics and Research Laboratory Hospital Universitari Arnau de Vilanova University of Lleida IRBLleida CIBERONC Lleida Spain

Department of Pathology Canisius Wilhelmina Hospital Nijmegen The Netherlands

Department of Pathology Elisabeth TweeSteden Hospital Tilburg The Netherlands

Department of Pathology Ghent University Hospital Cancer Research Institute Ghent Ghent Belgium

Department of Pathology Radboud University Medical Center Nijmegen The Netherlands

Department of Pathology University Hospital Brno and Masaryk University Brno Czech Republic

Department of Pathology University of Turku Turku Finland

Institute of Pathology University Medical Center Freiburg Germany

Obstetrics and Gynecology Department Bichat Claude Bernard Hospital Paris France

Pathology Department Vall Hebron University Hospital CIBERONC Barcelona Spain

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025008
003      
CZ-PrNML
005      
20201222155009.0
007      
ta
008      
201125s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pmed.1003111 $2 doi
035    __
$a (PubMed)32413043
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Reijnen, Casper $u Department of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands. Department of Obstetrics and Gynaecology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
245    10
$a Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study / $c C. Reijnen, E. Gogou, NCM. Visser, H. Engerud, J. Ramjith, LJM. van der Putten, K. van de Vijver, M. Santacana, P. Bronsert, J. Bulten, M. Hirschfeld, E. Colas, A. Gil-Moreno, A. Reques, G. Mancebo, C. Krakstad, J. Trovik, IS. Haldorsen, J. Huvila, M. Koskas, V. Weinberger, M. Bednarikova, J. Hausnerova, AAM. van der Wurff, X. Matias-Guiu, F. Amant, ENITEC Consortium, LFAG. Massuger, MPLM. Snijders, HVN. Küsters-Vandevelde, PJF. Lucas, JMA. Pijnenborg,
520    9_
$a BACKGROUND: Bayesian networks (BNs) are machine-learning-based computational models that visualize causal relationships and provide insight into the processes underlying disease progression, closely resembling clinical decision-making. Preoperative identification of patients at risk for lymph node metastasis (LNM) is challenging in endometrial cancer, and although several biomarkers are related to LNM, none of them are incorporated in clinical practice. The aim of this study was to develop and externally validate a preoperative BN to predict LNM and outcome in endometrial cancer patients. METHODS AND FINDINGS: Within the European Network for Individualized Treatment of Endometrial Cancer (ENITEC), we performed a retrospective multicenter cohort study including 763 patients, median age 65 years (interquartile range [IQR] 58-71), surgically treated for endometrial cancer between February 1995 and August 2013 at one of the 10 participating European hospitals. A BN was developed using score-based machine learning in addition to expert knowledge. Our main outcome measures were LNM and 5-year disease-specific survival (DSS). Preoperative clinical, histopathological, and molecular biomarkers were included in the network. External validation was performed using 2 prospective study cohorts: the Molecular Markers in Treatment in Endometrial Cancer (MoMaTEC) study cohort, including 446 Norwegian patients, median age 64 years (IQR 59-74), treated between May 2001 and 2010; and the PIpelle Prospective ENDOmetrial carcinoma (PIPENDO) study cohort, including 384 Dutch patients, median age 66 years (IQR 60-73), treated between September 2011 and December 2013. A BN called ENDORISK (preoperative risk stratification in endometrial cancer) was developed including the following predictors: preoperative tumor grade; immunohistochemical expression of estrogen receptor (ER), progesterone receptor (PR), p53, and L1 cell adhesion molecule (L1CAM); cancer antigen 125 serum level; thrombocyte count; imaging results on lymphadenopathy; and cervical cytology. In the MoMaTEC cohort, the area under the curve (AUC) was 0.82 (95% confidence interval [CI] 0.76-0.88) for LNM and 0.82 (95% CI 0.77-0.87) for 5-year DSS. In the PIPENDO cohort, the AUC for 5-year DSS was 0.84 (95% CI 0.78-0.90). The network was well-calibrated. In the MoMaTEC cohort, 249 patients (55.8%) were classified with <5% risk of LNM, with a false-negative rate of 1.6%. A limitation of the study is the use of imputation to correct for missing predictor variables in the development cohort and the retrospective study design. CONCLUSIONS: In this study, we illustrated how BNs can be used for individualizing clinical decision-making in oncology by incorporating easily accessible and multimodal biomarkers. The network shows the complex interactions underlying the carcinogenetic process of endometrial cancer by its graphical representation. A prospective feasibility study will be needed prior to implementation in the clinic.
650    _2
$a senioři $7 D000368
650    _2
$a Bayesova věta $7 D001499
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a nádory endometria $x patologie $7 D016889
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a prospektivní studie $7 D011446
650    _2
$a receptory pro estrogeny $x metabolismus $7 D011960
650    _2
$a receptory progesteronu $7 D011980
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a hodnocení rizik $7 D018570
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Gogou, Evangelia $u Department of Computing Sciences, Radboud University, Nijmegen, The Netherlands.
700    1_
$a Visser, Nicole C M $u Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
700    1_
$a Engerud, Hilde $u Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway. Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
700    1_
$a Ramjith, Jordache $u Department for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands.
700    1_
$a van der Putten, Louis J M $u Department of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands.
700    1_
$a van de Vijver, Koen $u Department of Pathology, Ghent University Hospital, Cancer Research Institute Ghent, Ghent, Belgium.
700    1_
$a Santacana, Maria $u Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, CIBERONC, Lleida, Spain.
700    1_
$a Bronsert, Peter $u Institute of Pathology, University Medical Center, Freiburg, Germany.
700    1_
$a Bulten, Johan $u Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
700    1_
$a Hirschfeld, Marc $u Department of Obstetrics and Gynecology, University Medical Center, Freiburg, Germany. Institute of Veterinary Medicine, Georg-August-University, Goettingen, Germany.
700    1_
$a Colas, Eva $u Biomedical Research Group in Gynecology, Vall Hebron Institute of Research, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain.
700    1_
$a Gil-Moreno, Antonio $u Biomedical Research Group in Gynecology, Vall Hebron Institute of Research, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain. Gynecological Department, Vall Hebron University Hospital, CIBERONC, Barcelona, Spain.
700    1_
$a Reques, Armando $u Pathology Department, Vall Hebron University Hospital, CIBERONC, Barcelona, Spain.
700    1_
$a Mancebo, Gemma $u Department of Obstetrics and Gynecology, Hospital del Mar, PSMAR, Barcelona, Spain.
700    1_
$a Krakstad, Camilla $u Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway. Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
700    1_
$a Trovik, Jone $u Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway. Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
700    1_
$a Haldorsen, Ingfrid S $u Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway. Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Bergen, Norway.
700    1_
$a Huvila, Jutta $u Department of Pathology, University of Turku, Turku, Finland.
700    1_
$a Koskas, Martin $u Obstetrics and Gynecology Department, Bichat-Claude Bernard Hospital, Paris, France.
700    1_
$a Weinberger, Vit $u Department of Gynecology and Obstetrics, University Hospital in Brno and Masaryk University, Brno, Czech Republic.
700    1_
$a Bednarikova, Marketa $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
700    1_
$a Hausnerova, Jitka $u Department of Pathology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
700    1_
$a van der Wurff, Anneke A M $u Department of Pathology, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.
700    1_
$a Matias-Guiu, Xavier $u Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, CIBERONC, Lleida, Spain.
700    1_
$a Amant, Frederic $u Department of Oncology, KU Leuven, Leuven, Belgium. Center for Gynecologic Oncology Amsterdam, Netherlands Cancer Institute and Amsterdam University Medical Center, The Netherlands.
700    1_
$a Massuger, Leon F A G $u Department of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands.
700    1_
$a Snijders, Marc P L M $u Department of Obstetrics and Gynaecology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
700    1_
$a Küsters-Vandevelde, Heidi V N $u Department of Pathology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
700    1_
$a Lucas, Peter J F $u Department of Data Science, University of Twente, Enschede, The Netherlands.
700    1_
$a Pijnenborg, Johanna M A $u Department of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands.
710    2_
$a ENITEC Consortium
773    0_
$w MED00008921 $t PLoS medicine $x 1549-1676 $g Roč. 17, č. 5 (2020), s. e1003111
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32413043 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155005 $b ABA008
999    __
$a ok $b bmc $g 1599153 $s 1115694
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 17 $c 5 $d e1003111 $e 20200515 $i 1549-1676 $m PLoS medicine $n PLoS Med $x MED00008921
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace